Serum XXXX is associated with multiple @entity174 in @entity6 .

@entity1 @entity5272 @entity5735 @entity174 @entity6 @entity79 @entity3929 @entity1011
OBJECTIVE: @entity1 with @entity6 ( @entity6 ) have a high risk of @entity174 although they have slightly higher @entity79 ( @entity79 ). There is no evidence that @entity5735 ( @entity5735 ) is involved in the @entity79 of the @entity1 . The aim of this study is to investigate the association between serum @entity5735 levels and @entity174 ( @entity174 ) in @entity1 with @entity6 . DESIGN: We conducted a cross-sectional study and investigated the relationships between serum @entity5735 levels versus @entity79 at lumbar spine, femoral neck and radius, bone turnover markers, and presence of @entity174 in 204 Japanese male @entity1 . RESULTS: Multiple regression analyses adjusted for confounders such as age, duration of @entity6 , body mass index, serum @entity1011 , HbA1c, serum albumin, log( @entity3929 transaminase), and log(C-reactive protein) showed that serum @entity5735 was positively associated with bone formation markers (bone-specific alkaline phosphatase and osteocalcin) as well as a bone resorption marker [ @entity5272 -resistant acid phosphatase 5b (TRACP5b)] (b=0.25, p<0.01; b=0.17, p<0.05; and b=0.30, p<0.01, respectively), but not @entity79 at each site. Multivariate logistic regression analyses adjusted for the confounders described above revealed that serum @entity5735 levels were associated with the presence of multiple @entity174 (odds ratio 1.61, 95% confidential interval 1.05-2.49 per SD increase, p<0.05). This association was still significant after additional adjustment for any sites of @entity79 or bone turnover markers except for TRACP-5b. CONCLUSIONS: We firstly showed that high level of serum @entity5735 is associated with prevalent multiple @entity174 independently of @entity79 and bone formation in @entity1 with @entity6 . This article is protected by copyright. All rights reserved.
